Deals in Depth: April 2011
Executive Summary
Meda paid $420 million in cash for exclusive worldwide rights to Novartis' dermatitis cream Elidel. J&J's acquisition of orthopedic device company Synthes topped the acquisition list at $21.7 billion. The $1.6 billion in biopharma financing was outshone by Royalty Pharma's $487 million purchase of Cubicin and Lexiscan royalties. Similarly the one outlier device transaction - DJO's $300 million notes offering - represented 64% of the $471 million in device fundraising.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.